Universal Cells
Focus: Universal Cells is a publicly-traded biotechnology company specializing in non-immunogenic cell therapies targeting respiratory, cardiovascular, infectious, rare, and oncology indications. The company is based in Seattle and was part of Astellas' stem cell platform before recent restructuring.
Profile data last refreshed 51m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
2
Should You Work at Universal Cells?
AI assessmentAvoid until organizational stability is demonstrated; recent 50-person layoff and minimal pipeline activity indicate this may be a distressed asset rather than a growth opportunity.
Why Work Here
- Leading position in non-immunogenic cell therapy, a cutting-edge modality with applications across five major therapeutic areas
- Public-company resources and regulatory experience with approved NDA products already in peak lifecycle
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Help build intelligence for Universal Cells
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.